BLACK WEEKSFlakonai −15% · rinkiniai −10% · kita −5%su koduNemokamas siuntimas Vokietijoje nuo €200

Šis puslapis išverstas automatiškai ir jame gali būti klaidų. Ar lietuvių kalba yra jūsų gimtoji? Mielai sulauksime jūsų atsiliepimų ir pataisymų.Siųsti atsiliepimą

The Peptide Desk The Peptide Desk
Orforglipron, produkto nuotrauka

Laboratorijos ataskaita

PDF
Ištirta
Ištirta
Orforglipron 6mg × 100 Tabs
Laboratorija
Analiza Białek
Data
October 2026
Rezultatas
5.91 mg per tablet (6 mg label)
Užsakymo nr.
Slaptažodis

Ištirta nepriklausomai, su slaptažodžiu galima patikrinti tiesiogiai laboratorijoje.

GLP-1 Oral

Orforglipron

GLP-1 Oral

Užsakymas

Vieneto kaina - Nemokamas siuntimas Vokietijoje nuo 200 € Black Weeks metu
  • DHL su sekimu
  • Diskreti pakuotė

4.6 iš 5 TrustpilotAtsiliepimų: 73

Trumpai

Orforglipron skaičiais

Pagrindiniai rodikliai iš mūsų žinyno.

Visas žinyno įrašas
Class
GLP-1 agonistsmall molecule, oral
Half-life
longdosed daily
Use
Oralin mg/day
Sizes
3 sizes6mg/90tabs, 6mg/100tabs, 12mg/100tabs

Žinios

Viskas apie Orforglipron

FAQ

Dažnai užduodami klausimai

Šaltiniai kiekvienam atsakymui: žinyno įrašas

Dar turite klausimų?

Parašykite mums, mūsų komanda jums padės.

How does Orforglipron differ from semaglutide as a tablet?

Semaglutide is a peptide and is poorly absorbed in the stomach, which is why a strict fasting rule applies. Orforglipron is a small molecule that acts on the same GLP-1 receptor. With food the absorbed amount was only about 18 to 24 percent lower in two studies, half-life and time to peak stayed the same. The US prescribing information states no clinically relevant food effect.

Is Orforglipron approved?

Yes, in the US since 1 April 2026 for long-term weight reduction in adults with obesity or with overweight and at least one related condition. Applications were under review in the EU, Japan and Canada in 2026, also for type 2 diabetes. The approved tablets have different strengths than the capsules used in the trials, so the numbers are not directly comparable.

How much did weight drop in the trials?

In the phase 3 trial with 3,127 adults without diabetes weight fell by 7.5, 8.4 and 11.2 percent over 72 weeks depending on the level, by 2.1 percent on placebo. In the highest level 54.6 percent lost at least a tenth of their weight and 18.4 percent at least a fifth. With type 2 diabetes the loss was 5.1 to 9.6 percent. Waist size, systolic blood pressure and blood lipids improved.

How does it perform in type 2 diabetes?

In early type 2 diabetes HbA1c fell by 1.24 to 1.48 percentage points over 40 weeks, by 0.41 on placebo. There were no severe hypoglycaemias. In a 52-week head-to-head trial both tested Orforglipron levels lowered HbA1c more than both levels of oral semaglutide, 1.91 against 1.47 percentage points comparing the higher levels.

Which side effects were seen?

Mainly gastrointestinal complaints such as nausea, constipation, diarrhoea and vomiting, mostly mild to moderate and mainly during dose escalation. Compared with oral semaglutide 58 to 59 percent had such complaints against 37 to 45 percent. 9 to 10 percent stopped against 4 to 5 percent. Pulse rose by up to 4.7 beats per minute on average.

Why is one tablet a day enough?

Orforglipron stays in the blood for a long time. In the first human study the half-life after several weeks was 48 to 68 hours, the US prescribing information gives 29 to 49 hours. A steady level is reached after about a week. It is broken down mainly in the liver via CYP3A4, so interactions with drugs that slow down or speed up this enzyme matter.

Does it help to keep weight off after injection therapy?

One trial tested this: people who switched to Orforglipron after 72 weeks of injected tirzepatide or semaglutide kept on average 74.7 and 79.3 percent of their previous loss after one year, 49.2 and 37.6 percent on placebo. There was no arm that continued the injection and the trial ran for one year only.

Susiję

Susiję produktai